Publication of a paper and presentation at a conference on the results of the Phase 1/2a clinical trial of SB623 in patients with chronic ischemic stroke
First written in FY2017-Q2. 3 of 6 entries say "Restated". Latest entry: FY2018-Q3.
No other company in this theme has enough history to compare yet.
- FY2018-Q3RestatedAnnual report
「Along with this progress, in June 2016, a paper on the results at 12 months after treatment in the SB623 chronic ischemic stroke Phase 1/2a clinical trial was published in STROKE, a medical journal published by the American Heart Association. Subsequently, in February 2017, the program received third place in the Association's 2016 Innovation Award, attracting the attention of many healthcare professionals and media organizations.」
The publication of the paper on the SB623 chronic ischemic stroke Phase 1/2a trial and its receipt of third place in the American Heart Association's 2016 Innovation Award in February 2017 have been reconfirmed. - FY2018-Q2RestatedAnnual report
「In June 2016, a paper on the results at 12 months after treatment in the SB623 chronic ischemic stroke Phase 1/2a clinical trial was published in STROKE, a medical journal published by the American Heart Association. Subsequently, in February 2017, the program received third place in the Association's 2016 Innovation Award, attracting the attention of many healthcare professionals and media organizations.」
The publication of the paper on the SB623 chronic ischemic stroke Phase 1/2a trial and its receipt of third place in the American Heart Association's 2016 Innovation Award in February 2017 have been reconfirmed. - FY2018-Q1AdvancedAnnual report
「In June 2016, a paper on the results at 12 months after treatment in the SB623 chronic ischemic stroke Phase 1/2a clinical trial was published in STROKE, a medical journal published by the American Heart Association. In February 2017, the program received third place in the American Heart Association's 2016 Innovation Award, attracting the attention of many healthcare professionals and media organizations.」
In addition to the existing publication, the program received third place in the American Heart Association's 2016 Innovation Award in February 2017. - FY2017AdvancedAnnual report
「In June 2016, the results at 12 months after treatment in the SB623 chronic ischemic stroke Phase 1/2a clinical trial were published in STROKE, a medical journal published by the American Heart Association. The content of the paper was reported at the ISSCR conference held in June 2016 and at the annual meeting of the American Congress of Rehabilitation Medicine Conference in November 2016.」
In addition to the existing publication and ISSCR presentation, a report was presented at the annual meeting of the American Congress of Rehabilitation Medicine Conference in November 2016. - FY2017-Q3RestatedAnnual report
「In June 2016, the results at 12 months after treatment in the SB623 chronic ischemic stroke Phase 1/2a clinical trial were published in STROKE, a specialist journal published by the American Heart Association, and the results of the same trial were also presented at the ISSCR conference held in San Francisco.」
The results at 12 months in the SB623 chronic ischemic stroke Phase 1/2a trial were again reported as having been published in a specialist journal and presented at an international conference. - FY2017-Q2First statedAnnual report
「In June 2016, the results at 12 months after treatment of patients enrolled in the SB623 chronic ischemic stroke Phase 1/2a clinical trial were published in STROKE, a specialist journal published by the American Heart Association, and the results of the same trial were also presented at the International Society for Stem Cell Research (ISSCR) conference held in San Francisco that month.」
The results at 12 months after treatment in the SB623 chronic ischemic stroke Phase 1/2a trial were published in a specialist journal and presented at an international conference.